Report cover image

Global Celiac Disease Drugs Market 2022-2026

Publisher TechNavio
Published Jul 29, 2022
Length 120 Pages
SKU # INF17336589

Description

Global Celiac Diseases Drugs Market 2022-2026

Technavio has been monitoring the celiac disease drugs market and it is poised to grow by $ 601.57 mn during 2022-2026, accelerating at a CAGR of 16.95% during the forecast period. Our report on the celiac disease drugs market provides a holistic analysis, of market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by higher consumption of gluten-containing food, increasing prevalence of celiac disease, and government initiatives.

The celiac disease drugs market analysis includes type segment and geographic landscape.

Technavio's celiac diseases drugs market is segmented as below:

By Type
  • The first line of treatment
  • The second line of treatment
By Geographical Landscape
  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the inorganic growth strategies as one of the prime reasons driving the celiac diseases drugs market growth during the next few years. Also, a robust pipeline and rise in pharmaceutical expenditure will lead to sizable demand in the market.

Technavio presents a detailed picture of the market through study, synthesis, and summation of data from multiple sources by analyzing key parameters. Our report on the celiac diseases drugs market covers the following areas:
  • Celiac diseases drugs market sizing
  • Celiac diseases drugs market forecast
  • Celiac diseases drugs market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading celiac diseases drugs market vendors that include 9 Meters Biopharma Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., AMYRA Biotech AG, Avaxia Biologics Inc., BioLineRx Ltd., Bristol Myers Squibb Co., Calypso Biotech, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Immunogenics LLC, Johnson and Johnson, Precigen Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Vactech Oy, Zedira GmbH, and Artielle Immunotherapeutics Inc. Also, the celiac disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market through study, synthesis, and summation of data from multiple sources by analyzing key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

120 Pages
    • Market overview
    • Market ecosystem
    • Market definition
    • Market segment analysis
    • Market size 2021
    • Market outlook: Forecast for 2021-2026
    • Five forces summary
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
    • Market segments
    • Comparison by Therapy
    • First line treatment - Market size and forecast 2021-2026
    • Second line treatment - Market size and forecast 2021- 2026
    • Market opportunity by Therapy
    • Customer landscape overview
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2021-2026
    • Europe - Market size and forecast 2021-2026
    • Asia - Market size and forecast 2021-2026
    • Rest of World (ROW) - Market size and forecast 2021- 2026
    • US - Market size and forecast 2021-2026
    • Canada - Market size and forecast 2021-2026
    • Germany - Market size and forecast 2021-2026
    • UK - Market size and forecast 2021-2026
    • France - Market size and forecast 2021-2026
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Impact of drivers and challenges
    • Market trends
    • Overview
    • Vendor landscape
    • Landscape disruption
    • Industry risks
    • Vendors covered
    • Market positioning of vendors
    • Amgen Inc.
    • AMYRA Biotech AG
    • BioLineRx Ltd.
    • Bristol Myers Squibb Co.
    • Calypso Biotech
    • GlaxoSmithKline Plc
    • Immunogenics LLC
    • Johnson and Johnson
    • Sanofi
    • Takeda Pharmaceutical Co. Ltd.
    • Scope of the report
    • Inclusions and exclusions checklist
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us